

US EPA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

CASWELL FILE

780

1

MAY 1 1996

OFFICE OF  
PREVENTION, PESTICIDES AND  
TOXIC SUBSTANCES

**MEMORANDUM**

**SUBJECT:** Review of Additional Data Submitted for a Subchronic Neurotoxicity Study with Metam Sodium.

**EPA Identification Numbers:**

MRID: 43875201 and 43875202  
P.C. Code: 039003

DP Barcode: D223577  
Submission: S501122

**TO:** Kathleen Depukat / Tom Myers  
Product Manager # 51  
Special Review and Reregistration Division (7508W)

**FROM:** Timothy F. McMahon, Ph.D. *T. McMahon* 4/24/96  
Pharmacologist, Review Section I  
Toxicology Branch II, Health Effects Division (7509C)

**THRU:** Yiannakis M. Ioannou, Ph.D. *Y. M. Ioannou* 4/24/96  
Section Head, Review Section I  
Toxicology Branch II, Health Effects Division (7509C)

and

Stephanie R. Irene, Ph.D.  
Acting Chief, Toxicology Branch II  
Health Effects Division (7509C)

*Stephanie R. Irene*  
4/30/96

**Registrant:** Metam Sodium Task Force

**Action Requested:** Review of addenda submitted for a subchronic neurotoxicity study with Metam Sodium.



Recycled/Recyclable  
Printed with Soy/Canola Ink on paper that  
contains at least 50% recycled fiber

1

### Data Summary

The registrant (Metam Sodium Task Force) submitted two addenda in relation to a subchronic neurotoxicity study conducted with Metam Sodium. The first addendum referred to re-examination of selected brain tissue using a set of criteria developed for achieving consistency between studies of this type. The second addendum referred to clinical observations. The original report for this study only reported positive findings for clinical observation assessments. The submitted addendum was prepared to report all clinical observation data, including negative findings, generated as part of the Functional Observational Battery.

In the original review of the subchronic neurotoxicity study (MRID # 43248801), no significant macroscopic or microscopic pathology was noted, and no significant clinical observations were noted. The data presented in these two addenda do not alter any of the original conclusions from review of the subchronic neurotoxicity study.